The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family
References (39)
- et al.
A separation method for the assay of adenylylcyclase, intracellular cyclic AMP and cyclic-AMP phosphodiesterase using tritium-labeled substrates
Anal. Bioch.
(1992) - et al.
Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors
Trends Pharm. Sci.
(1990) - et al.
Interactions offormylmethionyl- leucyl-phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes
FEBS Lett.
(1989) Transmembrane signals in the activation of T-lymphocytes by lectin mitogens
Mol. Immunol.
(1988)- et al.
Characterization of the structure of a low Xn, M, rolipram-sensitive cAMP phosphodiesterase
J. Biol. Chem.
(1992) - et al.
Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes
Trends Pharm. Sci.
(1991) - et al.
Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst
J. Allergy Clin. Immunol.
(1990) - et al.
Multiple high-affinity cAMP phosphodiesterases in human T-lymphocytes
Bioch. Pharm.
(1991) - et al.
Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell
J. Biol. Chem.
(1991) - et al.
Cyclic adenosine 3':5'-monophosphate phosphodiesterase
J. Biol. Chem.
(1976)
Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function
Pharmac. Ther.
Concanavalin A stimulates the rolipram-sensitive isoforms of cyclic nucleotide phosphodiesterase in rat thymic lymphocytes
Bioch. Biophys. Res. Commun.
Differential inhibition of human neutrophil functions: role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase
Bioch. Pharm.
Identification of a conserved domain among cyclic nucleotide phosphodiesterases from diverse species
Molecular analysis of cDNA clones and the corresponding genomic coding sequences of the Drosophila dllnce+ gene, the structural gene for cAMP phospho-diesterase
Intracellular events during lymphocyte activation
Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase
Hormonal regulation of cyclic nucleotide phosphodiesterases
Endocrine Reviews.
Cited by (72)
Phosphodiesterases as therapeutic targets for respiratory diseases
2019, Pharmacology and TherapeuticsCitation Excerpt :With the exception of PDE4A1, all other PDE4A isoforms have been detected in the lung, especially in inflammatory cells, fibroblasts and pulmonary artery smooth muscle cells (shown in Table 1) (Barber et al., 2004; Mackenzie et al., 2008; Millen, MacLean, & Houslay, 2006; Sachs et al., 2007). The Pde4b family is comprised of a super-short form PDE4B5 (Cheung et al., 2007), a short isoform PDE4B2 (McLaughlin, Cieslinski, Burman, Torphy, & Livi, 1993; Obernolte et al., 1993) and the long isoforms PDE4B1 (Bolger et al., 1993), PDE4B3 (Huston et al., 1997) and PDE4B4 (Shepherd et al., 2003). PDE4B shows ubiquitous expression, and is especially highly detected in the inflammatory cells, the brain and the testis (Cheung et al., 2007).
A reporter gene assay for screening of PDE4 subtype selective inhibitors
2007, Biochemical and Biophysical Research CommunicationsCitation Excerpt :These Zeocin resistant clones were screened by Western blot analysis using PDE4 subtype selective antibodies. These subtype selective antibodies recognize an epitope in the C-terminal region of a PDE4 subtype that is not common with the other three PDE4 subtypes [9,18]. Hence, these subtype selective antibodies recognizing an epitope in the C-terminal region of a PDE4 subtype, are important tool to detect the expression of a particular PDE4 subtype in a over-expressing recombinant cell line.
Phosphodiesterase 4B
2007, xPharm: The Comprehensive Pharmacology ReferenceCyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents
2006, Pharmacology and TherapeuticsImprovement of therapeutic index of phosphodiesterase type IV inhibitors as anti-asthmatics
2003, Bioorganic and Medicinal Chemistry LettersDisease activated drugs: A new concept for the treatment of asthma
2001, Bioorganic and Medicinal Chemistry